Beigene logo

BGNE - Beigene News Story

$311.97 -2.0  -0.6%

Last Trade - 07/05/21

Sector
Healthcare
Size
Large Cap
Market Cap £20.47bn
Enterprise Value £17.51bn
Revenue £221.1m
Position in Universe 458th / 6858

BRIEF-Beigene Updated On Phase 2 Clinical Trial Of Zanubrutinib In Patients With Covid-19-Related Pulmonary Distress

Thu 8th April, 2021 11:15pm
April 9 (Reuters) - Beigene Ltd  6160.HK :
    * BEIGENE LTD - UPDATE ON PHASE 2 CLINICAL TRIAL OF
ZANUBRUTINIB
IN PATIENTS WITH COVID-19-RELATED PULMONARY DISTRESS
    * BEIGENE LTD- TRIAL DID NOT MEET CO-PRIMARY EFFICACY
ENDPOINTS;
NO NEW SAFETY SIGNALS IDENTIFIED


Further company coverage:  6160.HK 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.